Dyax Corp. Announces Publication of Scientific Data for DX-2930 in Peer-Reviewed Journals
July 23 2014 - 8:00AM
Business Wire
Dyax Corp. (NASDAQ: DYAX) today announced the online publication
of scientific data for DX-2930, an investigational fully human
monoclonal antibody inhibitor of plasma kallikrein (pKal), in two
peer-reviewed journals. Dyax, a biopharmaceutical company focused
on hereditary angioedema (HAE) and other plasma-kallikrein-mediated
disorders, is developing DX-2930 as a subcutaneous injection for
prevention of HAE attacks.
The first paper titled “A Phase 1 Study Investigating DX-2930 in
Healthy Subjects” by Chyung et al. was published online in the
Annals of Allergy, Asthma and Immunology. The paper describes the
positive results from the first-in-human clinical study of DX-2930
which met all of its objectives of assessing safety, tolerability
and pharmacokinetics of this investigational drug candidate. These
data indicate that DX-2930 has a long half-life in humans and thus
the potential for prophylactic inhibition of pKal activity for the
therapeutic treatment of HAE. DX-2930 is now being evaluated in a
Phase 1b study in patients with HAE. The complete publication can
be accessed online here.
The second paper titled “Inhibition of Plasma Kallikrein by a
Highly Specific, Active Site Blocking Antibody” by Kenniston et al.
was published online in The Journal of Biological Chemistry. The
paper describes the discovery and preclinical evaluation of DX-2930
as a long-acting inhibitor of pKal proteolytic activity. This paper
is expected to appear in the September 2014 (Volume [289], Issue
[29]) print issue of the journal. The complete publication can be
accessed online here.
Dr. Burt Adelman, Executive Vice President of Research and
Development and Chief Medical Officer, commented: “We are delighted
to have two important, peer-reviewed papers published in these
prestigious scientific journals. Publication of these papers
confirms the significance of DX-2930 in the scientific community.
These data, combined with data that will be obtained from the
ongoing Phase 1b study, will inform and guide the future clinical
development of DX-2930.”
About DX-2930
DX-2930 is a novel, fully human monoclonal antibody inhibitor of
plasma kallikrein (pKal). Uncontrolled pKal activity leads to
excessive generation of bradykinin, a vasodilator thought to be
responsible for the localized swelling, inflammation and pain
characteristically associated with HAE. Dyax is currently
developing DX-2930 as a subcutaneous injection for the prevention
of HAE attacks and expects to report data from a Phase 1b trial
early in 2015.
About HAE
HAE is a rare acute inflammatory condition characterized by
episodes of severe, often painful swelling affecting the
extremities, gastrointestinal tract, genitalia, and larynx. HAE is
caused by low or dysfunctional levels of C1 esterase inhibitor
(C1-INH), a naturally occurring molecule that inhibits plasma
kallikrein, a key mediator of inflammation, and other serine
proteases in the blood. HAE is estimated to affect up to 1 in
50,000 individuals. Learn more at www.HAEHope.com.
About Dyax
Dyax is a fully integrated biopharmaceutical company focused on
the discovery, development and commercialization of novel
biotherapeutics for unmet medical needs. The Company currently
markets KALBITOR® for the treatment of acute attacks of hereditary
angioedema (HAE) in patients 12 years of age and older. Dyax is
also developing DX-2930 for the prophylactic treatment of HAE.
Both KALBITOR and DX-2930 were identified using Dyax's patented
phage display technology. Dyax has broadly licensed this technology
and has a portfolio of product candidates being developed by our
licensees, which it refers to as the Licensing and Funded Research
Portfolio (LFRP). The Company is eligible to receive future
milestones and/or royalties dependent upon the development and
commercialization of these candidates. In April 2014, Dyax’s
licensee Lilly received FDA approval for CYRAMZA™ (ramucirumab) as
a single-agent treatment for patients with advanced gastric cancer
after prior chemotherapy, making this the first approved product
from Dyax’s LFRP.
For additional information about Dyax, please visit
www.dyax.com.
For additional information about KALBITOR, including full
prescribing information, please visit www.KALBITOR.com.
Disclaimer
This press release contains forward-looking statements,
including statements regarding the prospects for the clinical
development of DX-2930. Statements that are not historical facts
are based on Dyax’s current expectations, beliefs, assumptions,
estimates, forecasts and projections about the industry and markets
in which Dyax and its licensees compete. The statements contained
in this release are not guarantees of future performance and
involve certain risks, uncertainties and assumptions, which are
difficult to predict. Therefore, actual outcomes and results may
differ materially from what is expressed in such forward-looking
statements because of risks, uncertainties and assumptions involved
in any future projections. There are many factors that could cause
actual results to differ from these forward-looking statements,
including: risks and uncertainties relating to the clinical
development of DX-2930; Dyax's dependence on the expertise, effort,
priorities and contractual obligations of third parties in the
manufacture, quality control, storage and clinical development of
DX-2930; changing requirements and costs associated with Dyax's
planned research and development activities; competition from new
and existing treatments for HAE; the uncertainty of patent and
intellectual property protection; and other risk factors described
or referred to in Item 1A, “Risk Factors” in Dyax’s most recent
Annual Report on Form 10-K and other periodic reports filed with
the Securities and Exchange Commission. Dyax cautions investors not
to place undue reliance on the forward-looking statements contained
in this release. These statements speak only as of the date of this
release, and Dyax undertakes no obligations to update or revise
these statements, except as may be required by law.
Dyax, the Dyax logo and KALBITOR are registered trademarks of
Dyax Corp.
Dyax Corp.Jennifer Robinson, 617-250-5741Director, Investor
Relationsand Corporate Communicationsjrobinson@dyax.com
Dyax (NASDAQ:DYAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dyax (NASDAQ:DYAX)
Historical Stock Chart
From Apr 2023 to Apr 2024